Following a limited submission
AWMSG advice |
|||
Status: Recommended | |||
Icatibant acetate (Firazyr®) is recommended as an option for use within NHS Wales for the symptomatic treatment of acute attacks of hereditary angioedema (HAE) in adults, adolescents and children aged 2 years and older, with C1 esterase-inhibitor deficiency. This recommendation applies only in circumstances where the approved Wales Patient Access Scheme (WPAS) is utilised or where the list/contract price is equivalent or lower than the WPAS price. |
|||
|
|||
Medicine details |
|||
Medicine name | icatibant acetate (Firazyr®) | ||
Formulation | 30 mg solution for injection | ||
Reference number | 3293 | ||
Indication | Symptomatic treatment of acute attacks of hereditary angioedema (HAE) in adults, adolescents and children aged 2 years and older, with C1 esterase-inhibitor deficiency |
||
Company | Shire Pharmaceuticals | ||
BNF chapter | Respiratory system | ||
Submission type | Limited | ||
Status | Recommended | ||
Advice number | 0818 | ||
NMG meeting date | 11/04/2018 | ||
AWMSG meeting date | 23/05/2018 | ||
Date of issue | 12/06/2018 | ||
Date of last review | December 2021 | ||
Commercial arrangement | WPAS |